These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15616161)

  • 1. Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer.
    Szakács G; Gottesman MM
    Mol Interv; 2004 Dec; 4(6):323-5. PubMed ID: 15616161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
    Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
    Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
    L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
    Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.
    Wallqvist A; Connelly J; Sausville EA; Covell DG; Monks A
    Mol Pharmacol; 2006 Mar; 69(3):737-48. PubMed ID: 16332985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs.
    Staege MS; Banning-Eichenseer U; Weissflog G; Volkmer I; Burdach S; Richter G; Mauz-Körholz C; Föll J; Körholz D
    Exp Hematol; 2008 Jul; 36(7):886-96. PubMed ID: 18400362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
    Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
    Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting drug response based on gene expression.
    Robert J; Vekris A; Pourquier P; Bonnet J
    Crit Rev Oncol Hematol; 2004 Sep; 51(3):205-27. PubMed ID: 15331079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles.
    Duale N; Lindeman B; Komada M; Olsen AK; Andreassen A; Soderlund EJ; Brunborg G
    Mol Cancer; 2007 Aug; 6():53. PubMed ID: 17711579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.
    Andrews P; Zhao X; Allen J; Li F; Chang M
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):203-14. PubMed ID: 17447067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.
    Cheng TC; Manorek G; Samimi G; Lin X; Berry CC; Howell SB
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):384-95. PubMed ID: 16404635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
    Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model.
    Watson MB; Lind MJ; Smith L; Drew PJ; Cawkwell L
    Acta Oncol; 2007; 46(5):651-8. PubMed ID: 17562441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GBP1 overexpression is associated with a paclitaxel resistance phenotype.
    Duan Z; Foster R; Brakora KA; Yusuf RZ; Seiden MV
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):25-33. PubMed ID: 16028104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
    Whyte DB; Holbeck SL
    Biochem Biophys Res Commun; 2006 Feb; 340(2):469-75. PubMed ID: 16376301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting cancer drug response by proteomic profiling.
    Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
    Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
    Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
    J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.